<DOC>
	<DOCNO>NCT02045069</DOCNO>
	<brief_summary>This Phase II/III , Randomized , Double-Blind , Placebo-Controlled Study Efficacy Safety Ivermectin Children Adult patient Dengue Infection .</brief_summary>
	<brief_title>Efficacy Safety Ivermectin Against Dengue Infection</brief_title>
	<detailed_description>Patients confirm dengue infection meet inclusion exclusion criterion enrol study admit hospital . Patients randomly assign pre-specified ratio 1:1:1 one follow study group : ivermectin 200-400 µg/kg single daily dose 2 day , ivermectin 200-400 µg/kg single daily dose 3 day , placebo . Tablets ivermectin placebo administer 3 day . Clinical exam perform daily hospitalization blood sample collect hematology , clinical chemistry , serology , viral load quantitative nonstructural 1 ( NS1 ) antigen . Safety assessment conduct admission . Patients discharge one day fever subsidence ask return 2 week first dose study medication safety assessment blood sampling .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Ivermectin</mesh_term>
	<criteria>Adults age 15 great . History presence fever ( temperature &gt; 38°C ) ≤ 72 hr duration . Clinical suspicion dengue infection high fever without evidence suspect focus infection clinical examination . Positive NS 1 strip assay Clinically significant abnormal laboratory result deem unassociated dengue infection Clinical evidence history significant respiratory , metabolic , renal , hepatic , hematologic chronic disease History autoimmune , immune dysfunction disorder take warfarin Clinical suspicion bacterial infection Pregnancy lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>